首页> 外文OA文献 >OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

【2h】

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

机译：OA12.07 ROXO-292的临床活性，一种高度选择性的RET抑制剂，RET融合+非小细胞肺癌患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
G. Oxnard; V. Subbiah; K. Park; T. Bauer; L. Wirth; V. Velcheti; M. Shah; B. Besse; V. Boni; K. Reckamp; H. Loong; L. Bazhenova; B. Solomon; D. Tan; J. Patel; M. Johnson; A. Gazzah; T. Mok; S. Smith; B. Tuch; K. Ebata; E. Zhu; M. Nguyen; X. Huang; S. Cruickshank; S. Rothenberg; A. Drilon;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer [J] . G. Oxnard, V. Subbiah, K. Park, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：OA12.07 ROXO-292的临床活性，一种高度选择性的RET抑制剂，RET融合+非小细胞肺癌患者
2. OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases [J] . V. Velcheti, T. Bauer, V. Subbiah, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：OA 12.07 LOXO-292，一种有效的，高度选择性的RET抑制剂，在MKI抗性RET融合阳性肺癌患者，没有脑转移
3. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases [J] . Subbiah Vivek, Berry Jenny, Roxas Michael, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第1期

机译：RET抑制剂vandetanib联合mTOR抑制剂依维莫司在KIF5B-RET重排的具有脑转移的非小细胞肺癌中的全身和CNS活性
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Crippling Rapid Evolution of Metastasis and Drug Resistance in A549 Non-Small Cell Lung Cancer Cells with the Clinically Relevant HSP90 Inhibitor AUY922 [D] . Bacon, Nickolas. 2021

机译：临床相关的HSP90抑制剂Auy922，A549非小细胞肺癌细胞转移和耐药性快速演变和耐药性的快速演变
6. SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation [O] . Maria E Cabanillas, Lori J Wirth, Eric J Sherman, 2020

机译：Sun-LB75选择性RET抑制剂Selpercatinib（LOXO-292）的抗肿瘤活性在髓质甲状腺癌中是独立于特定的RET突变
7. SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation [O] . Maria E Cabanillas, Lori J Wirth, Eric J Sherman, 2020

机译：Sun-LB75选择性RET抑制剂Selpercatinib（LOXO-292）的抗肿瘤活性在髓质甲状腺癌中是独立于特定的RET突变

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅